

NYSE Takes Another Step to Facilitate Capital Raises In Light of Pandemic

May 19, 2020

On May 14, 2020, the New York Stock Exchange (the "NYSE") adopted a temporary rule waiving until June 30, 2020 additional key shareholder approval requirements for certain private investments in public equity ("PIPE") and similar transactions by companies impacted by COVID-19. The new waiver operates by creating a new "COVID-19 exception" to the so-called "20% rule" that is significantly broader than the existing "financial viability exception" and continues a trend of both major exchanges providing incremental additional flexibility to companies that require an immediate cash infusion to weather the COVID-19 pandemic. The new waiver is generally consistent with recent temporary relief adopted by Nasdaq^[1] and serves to supplement last month's temporary waiver by the NYSE of certain requirements of the 20% rule and the shareholder approval rule applicable to issuances by related parties.^[2]

The NYSE's 20% rule generally requires shareholder approval of PIPEs and other privately negotiated transactions that involve issuances of common stock (or securities convertible into or exercisable for common stock) equal to, following issuance, more than 20% of the outstanding shares of common stock or voting power existing before the issuance if the price is below a "minimum price" equal to the lower of (i) the most recent closing price at the time the purchase agreement is signed, or (ii) the average of the five most recent closing prices.

The NYSE requirements already have some flexibility for companies facing serious financial stress, but it is too narrow in most cases to help many companies during the current pandemic and economic situation. The existing "financial viability exception" allows a company to avoid prior shareholder approval if it can demonstrate to the NYSE that delay in securing stockholder approval would seriously jeopardize the financial viability of the enterprise. This exception imposes a high standard, and requires providing a detailed written analysis to the NYSE covering matters that could include the company's current cash position and ability to meet current obligations, as well as whether or not the company would be rescued or forced to file for bankruptcy if it did receive the relief.

By contrast, the new COVID-19 exception is available to companies that are materially impacted by COVID-19 and the governmental responses to it, but that may not qualify for the financial viability exception. For example, a company that needs additional cash so that it can continue to pay employees during a period of decreased or no revenue could qualify for the COVID-19 exception even if the company's viability may not otherwise be in jeopardy.

For a transaction to qualify for the COVID-19 exception, the delay in securing shareholder approval must:

- have a material adverse impact on the company's ability to maintain operations under its pre-COVID-19 business plan;
- result in workforce reductions;
- adversely impact the company's ability to undertake new initiatives in response to COVID-19; or
- seriously jeopardize the financial viability of the enterprise.

To rely on the COVID-19 exception, the company must also obtain prior approval of the NYSE. The company must also demonstrate to the NYSE that the need for the transaction is due to circumstances related to COVID-19 and that the company undertook a process designed to ensure that the proposed transaction represents the best terms available to the company and that the proceeds would not be used to fund an acquisition. As with the financial viability exception, the company's audit committee (or a comparable body comprised solely of independent, disinterested directors) must also approve the transaction and determine that it is in the best interest of shareholders.

In addition to the relatively lower qualification standard, another advantage of the COVID-19 exception as compared to the financial viability exception is that the prior public notice required for reliance on the exception is two business days as compared to 10 days.

However, unlike the financial viability exception, the COVID-19 exception does not also apply to the NYSE's other shareholder approval rules in relation to related parties, change of control and equity compensation (except to the limited extent necessary to facilitate, subject to conditions, the participation in the transaction by officers, directors and other affiliates under circumstances that would otherwise require shareholder approval in a qualifying transaction). In structuring any transaction intended to qualify for the COVID-19 exception, close attention should be paid to these other rules, particularly the change of control rule which effectively requires prior approval of, among other potential issuances, any issuance that would result in an investor (or group) actually or potentially acquiring more than 20% of the outstanding shares of common stock or voting power *after* the issuance, particularly when the investor (or group) would then also have the largest ownership position.

* * *

For a listed company facing urgent liquidity needs, from an imminent debt maturity to working capital necessary to continue operating, a PIPE or similar transaction, if structured appropriately, is a fast, precise and flexible tool to address those needs. This new rule should facilitate even more PIPEs and similar transactions that can create lifelines for companies impacted by the pandemic.

For more information, please see our recent client alerts [here](#) and [here](#), providing an overview and answers to a few of the initial questions that may be on the minds of companies and investors considering PIPEs and other alternative equity offerings in these volatile markets.

* * *

Proskauer's market leading Global Capital Markets Practice has experience acting for issuers, investment banks and investors in a wide variety of capital markets financing transactions, including PIPEs, both in the U.S. and in Europe. Please contact us if we can be of assistance.

Proskauer's cross-disciplinary, cross-jurisdictional Coronavirus Response Team is focused on supporting and addressing client concerns. Visit our [Coronavirus Resource Center](#) for guidance on risk management measures, practical steps businesses can take and resources to help manage ongoing operations.

[1] For further details on this waiver, please see our recent [memo](#) on the subject.

[2] For further details on this waiver, please see our recent [memo](#) on the subject.

[Related Professionals](#)

- **Peter Castellon**
Partner
- **Michael J. Choate**
Partner
- **Steven L. Lichtenfeld**
Partner
- **Ben D. Orlanski**
Partner
- **Antonio N. Piccirillo**
Partner
- **Frank Zarb**
Partner
- **Louis Rambo**
Partner